Effects of celecoxib and naproxen on renal function in the elderly

Archives of Internal Medicine

Volumn 160, Issue 10, 2000, Pages 1465-1470

  Whelton, Andrew ^a   Schulman, Gerald ^b   Wallemark, Carl ^c   Drower, Edward J ^c   Isakson, Peter C ^c   Verburg, Kenneth M ^c   Geis, G Steven ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; CELECOXIB; NAPROXEN; PROSTAGLANDIN E2; SODIUM;

AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN EXPERIMENT; KIDNEY FUNCTION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SODIUM URINE LEVEL; URINARY EXCRETION;

EID: 0034701938     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.160.10.1465     Document Type: Article

References (36)

1. Anti-arthritic medication usage: United States, 1991. Stat Bull Metrop Insur Co. 1992;73:25-34.
2. Felson DT. Epidemiology of hip and knee osteoarthritis. Epidemiol Rev. 1988; 10:1-28.
3. Beck LH. Changes in renal function with aging. Clin Geriatr Med. 1998;14:199-209.
4. Epstein M. Aging and the kidney. J Am Soc Nephrol. 1996;7:1106-1122.
5. Lash JP, Gardner C. Effects of aging and drugs on normal renal function. Coron Artery Dis. 1997;8:489-494.
6. Cooper K, Bennett WM. Nephrotoxicity of common drugs used in clinical practice. Arch Intern Med. 1987;147:1213-1218.
7. Blackshear JL, Davidman M, Stillman MT. Identification of risk for renal insufficiency from nonsteroidal anti-inflammatory drugs. Arch Intern Med. 1983;143: 1130-1134.
8. Sandler DP, Burr FR, Weinberg CR. Nonsteroidal anti-inflammatory drugs and the risk for chronic renal disease. Ann Intern Med. 1991;115:165-172.
9. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med. 1999;106(suppl 5B): 13S-24S.
10. Patrono C, Dunn MJ. The clinical significance of inhibition of renal prostaglandin synthesis. Kidney Int. 1987;32:1-12.
11. Crofford LJ. COX-1 and COX-2 tissue expression: implications and predictions. J Rheumatol. 1997;24(suppl 49):15-19.
12. Dubois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. FASEB J. 1998;12:1063-1073.
13. Kargman S, Charleson S, Cartwright M, et al. Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology. 1996;111:445-454.
14. Khan KNM, Venturini CM, Bunch RT, et al. Interspecies differences in renal localization of cyclooxygenase isoforms: implications in nonsteroidal anti-inflammatory drug-related nephrotoxicity. Toxicol Pathol. 1998;26:612-620.
15. Schafer Al. Effects of nonsteroidal anti-inflammatory therapy on platelets. Am J Med. 1999;106(suppl 5B):25S-36S.
16. Copeland RA, Williams JM, Giannaras J, et al. Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase. Proc Natl Acad Sci USA. 1994;91:11202-11206.
17. Gierse JK, Hauser SD, Creely DP, et al. Expression and selective inhibition of the constitutive and inducible forms of human cyclooxygenase. Biochem J. 1995; 305:479-484.
18. Raskin JB. Gastrointestinal effects of nonsteroidal anti-inflammatory therapy. Am J Med. 1999;106(suppl 5B):3S-12S.
19. Lefkowith JB. Cyclooxygenase-2 specificity and its clinical implications. Am J Med. 1999;106(suppl 5B):3S-12S.
20. Harris RC, McKanna JA, Akai Y, Jacobson HR, Dubois RN, Breyer MD. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest. 1994;6:2504-2510.
21. Vio CP, Cespedes C, Gallardo P, Masferrer JL. Renal identification of cyclooxygenase-2 in a subset of thick ascending limb cells. Hypertension. 1997;30:687-692.
22. O'Neill GP, Ford-Hutchinson AW. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett. 1993;330:156-160.
23. Kömhoff M, Gröne H-J, Klein T, Seyberth HW, Nüsing RM. Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function. Am J Physiol. 1997;272:F460-F468.
24. Simon LS, Lanza FL, Lipsky PE, et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum. 1998;41:1591-1602.
25. Hubbard R, Geis GS, Woods E, Yu S, Zhao W. Efficacy, tolerability and safety of celecoxib, a specific COX-2 inhibitor, in osteoarthritis [abstract]. Arthritis Rheum. 1998;41(suppl):S196.
26. Geis GS, Hubbard R, Callison D, Yu S, Zhao W. Safety and efficacy of celecoxib, a specific COX-2 inhibitor, in patients with rheumatoid arthritis [abstract]. Arthritis Rheum. 1998;41(suppl):S364.
27. Maher FT, Nolan NG, Elveback LR. Comparison of simultaneous clearances of 125-I-labeled sodium iothalamate (Glofil) and of inulin. Mayo Clin Proc. 1971; 46:690-691.
28. Sharma AK, Mills MS, Grey VL, Drummond KN. Infusion clearance of subcutaneous iothalamate versus standard renal clearance. Pediatr Nephrol. 1997;11: 711-713.
29. Jones B, Kenward MG. Design and Analysis of Crossover Trials. London, England: Chapman & Hall; 1994:60-66.
30. Whelton A, Stout RL, Spilman PS, Klassen DK. Renal effects of ibuprofen, piroxicam, and sulindac in patients with asymptomatic renal failure: a prospective, randomized, crossover comparison. Ann Intern Med. 1990;112:568-576.
31. Lamy PP. Renal effects of nonsteroidal anti-inflammatory drugs: heightened risk to the elderly. J Am Geriatr Soc. 1986;34:361-367.
32. Simon LS, Basch CM, Young DY, Robinson DR. Effects of naproxen on renal function in older patients with mild to moderate renal dysfunction. Br J Rheumatol. 1992;3:163-168.
33. Eriksson L, Sturfelt G, Thysell H, Wollheim FA. Effects of sulindac and naproxen on prostaglandin excretion in patients with impaired renal function and rheumatoid arthritis. Am J Med. 1990;89:313-321.
34. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA. 1999; 96:272-277.
35. Paulson S, Zhang J, Breau A, et al. Pharmacokinetics, tissue distribution, metabolism and excretion of celecoxib in rats. Drug Metab Dispos. In press.
36. Catella-Lawson F, McAdam BF, Morrison BW. et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther. 1999;289:735-741.